Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices 4521 

are to respond, including the use of 

appropriate automated electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the Office of 

Management and Budget, Office of 

Regulatory Affairs, New Executive 

Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact: Dr. 

Nancy Breen, Ph.D., Project Officer, 

Applied Research Program, Division of 

Cancer Control and Population Sciences 

NCI, NIH, EPN 4005, 6130 Executive 

Boulevard MSC 7344. Bethesda, 

Maryland 20852–7344, or call the nontoll-free number 301–696–8500 or Email your request, including your 

address to breenn@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

Dated: January 23, 2007. 

Rachelle Ragland-Greene, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 07–406 Filed 1–30–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Call for 

Nominations for the National Cancer 

Institute Director’s Consumer Liaison 

Group 

The National Cancer Institute (NCI) 

the Federal Government’s primary 

agency for cancer research, is seeking 

nominations for four (4) new members 

of the NCI Director’s Consumer Liaison 

Group (DCLG) which will be appointed 

in July, 2007. The DCLG helps NCI to 

identify appropriate advocates to serve 

on its program and policy advisory 

committees. 

The National Cancer Institute (NCI) 

formed the NCI Director’s Consumer 

Liaison Group (DCLG) in 1998 to advise 

and make recommendations to the NCI 

Director, from the perspective and 

viewpoint of cancer consumer 

advocates, on a wide variety of issues, 

programs, and research priorities. The 

DCLG gives cancer advocates a channel 

to voice their views and concerns. The 

DCLG is a 16-member chartered federal 

advisory committee that works with NCI 

to ensure that those who experience the 

burden of cancer also help to shape the 

course of the NCI’s research to eradicate 

it. Specifically the DCLG members: 

• Help develop and establish 

processes, mechanisms and criteria for 

identifying appropriate consumer 

advocates to serve on a variety of 

program and policy advisory 

committees responsible for advancing 

the mission of the NCI. 

• Serve as a primary forum for 

discussion issues and concerns and 

exchanging viewpoints that are 

important to the broad development of 

the NCI programming and research 

priorities. 

• Establish and maintain strong 

collaborations between the NCI and the 

cancer advocacy community to reach 

common goals. 

Eligibility Requirements: NCI looks for 

strong, highly qualified candidates who 

fulfill the following eligibility criteria: 

• Demonstrate involvement in the 

cancer experience as a cancer survivor, 

a caregiver to someone who has cancer, 

or as a professional or volunteer who 

works with cancer survivors, patients, 

or caregivers; 

• Have a constituency with which 

she/he regularly communicates on 

cancer issues and with which she/he is 

able to serve as a conduit for 

information, both to and from NCI. 

Nominees who meet the minimum 

eligibility requirements will be 

evaluated further based on the following 

qualities: 

• Cancer advocacy experience; ability 

to represent all cancer survivors; 

• Possession of strong leadership, 

communication, and collaboration 

skills; 

• Ability to advise on broad cross 

cutting cancer issues; 

• Ability to facilitate dialogue 

between NCI and the cancer advocacy 

community. 

DCLG members must be committed to 

participating in all activities of the 

DCLG which includes at least two 

meetings a year in Bethesda, MD. 

Characteristics of the DCLG. In 

addition to the criteria for individual 

candidates, the following characteristics 

of the DCLG as a group are balanced to 

ensure that it reflects the breadth and 

diversity of the consumer advocacy 

community: 

• Racial and ethnic balance 

• A broad mix of cancer sites 

• Expertise with advocacy 

organizations (local, regional, or 

national) 

• Geographical diversity 

• Gender 

• Age diversity 

Selection Process. A call for 

nominations is disseminated annually 

to a broad range of groups, including 

local, regional and national 

organizations, to encourage nominations 

of candidates reflecting the diversity 

sought for the DCLG. Individuals may 

nominate themselves. All nominees are 

screened for eligibility, and then 

evaluated according to the criteria. A 

list of highly qualified candidates who 

reflect balance and diversity of 

representation is forwarded to the 

Director, NCI who selects the DCLG 

members. The original members of the 

DCLG endorsed this process and the 

criteria developed to evaluate the 

applications of potential DCLG 

members, and this process is used to 

select future members. 

To receive a nomination package for 

the DCLG, send your name, advocacy/ 

voluntary organization affiliation (if 

any), address, phone number and E-mail 

information to: Palladian Partners, Inc., 

Attn: DCLG 2007 Selection Process, 

1010 Wayne Avenue, Suite 1200, Silver 

Spring, MD 20910, Phone: (301) 650–

8660, Fax: (301) 650–8676. 

Nominations must be postmarked by 

March 30, 2007. 

Dated: January 23, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy, National Institutes of 

Health. 

[FR Doc. 07–400 Filed 1–30–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis Panel, 

February 27, 2007, 12 p.m. to February 

27, 2007, 4 p.m., National Institutes of 

Health, 6130 Executive Blvd., Rockville, 

MD 20852 which was published in the 

Federal Register on December 28, 2006, 

71 FR 78214. 

The meeting notice is changed to 

reflect the change in the name of the 

committee from ‘‘SBIR Topic 230 

(Phases I & II)’’ to ‘‘SBIR, Synthesis 

Stable Isotope-Labeled Steroids as 

Internal Standards.’’ The meeting is 

closed to the public. 

mstockstill on PROD1PC62 with NOTICES